INVO Fertility, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
INVO Fertility, Inc. (IVF) reported Revenue from Contract with Customer, Excluding Assessed Tax of $1.64 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-20.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-05-20
- INVO Fertility, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $1.64M, a 4.15% increase year-over-year.
- INVO Fertility, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $1.71M, a 24.12% increase year-over-year.
- INVO Fertility, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $1.43M, a 47.01% increase year-over-year.
- INVO Fertility, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $1.84M, a 481.38% increase year-over-year.
- INVO Fertility, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $6.56M, a 117.21% increase from fiscal 2023.
- INVO Fertility, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $3.02M, a 267.38% increase from fiscal 2022.
- INVO Fertility, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $822.20K, a 80.24% decline from fiscal 2021.
- INVO Fertility, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $4.16M, a 301.06% increase from fiscal 2020.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-03-31 | $1.64M 10-Q · filed 2025-05-20 | $3.36M derived: sum of 2 quarters · filed 2025-05-20 | $4.79M derived: sum of 3 quarters · filed 2025-05-20 | $6.63M derived: sum of 4 quarters · filed 2025-05-20 |
| 2024-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-30 | $3.15M derived: sum of 2 quarters · filed 2025-04-30 | $4.98M derived: sum of 3 quarters · filed 2025-04-30 | $6.56M 10-K · filed 2025-04-30 |
| 2024-09-30 | $1.43M 10-Q · filed 2024-11-19 | $3.27M derived: sum of 2 quarters · filed 2024-11-19 | $4.85M 10-Q · filed 2024-11-19 | $6.23M derived: sum of 4 quarters · filed 2025-05-20 |
| 2024-06-30 | $1.84M 10-Q/A · filed 2024-11-19 | $3.41M 10-Q/A · filed 2024-11-19 | $4.79M derived: sum of 3 quarters · filed 2025-05-20 | $5.77M derived: sum of 4 quarters · filed 2025-05-20 |
| 2024-03-31 | $1.58M 10-Q · filed 2025-05-20 | $2.96M derived: sum of 2 quarters · filed 2025-05-20 | $3.93M derived: sum of 3 quarters · filed 2025-05-20 | $4.25M derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-30 | $2.36M derived: sum of 2 quarters · filed 2025-04-30 | $2.67M derived: sum of 3 quarters · filed 2025-04-30 | $3.02M 10-K · filed 2025-04-30 |
| 2023-09-30 | $974.89K 10-Q · filed 2024-11-19 | $1.29M derived: sum of 2 quarters · filed 2024-11-19 | $1.64M 10-Q · filed 2024-11-19 | $1.92M derived: sum of 4 quarters · filed 2024-11-19 |
| 2023-06-30 | $315.90K 10-Q/A · filed 2024-11-19 | $663.93K 10-Q/A · filed 2024-11-19 | $942.07K derived: sum of 3 quarters · filed 2024-11-19 | $1.18M derived: sum of 4 quarters · filed 2024-11-19 |
| 2023-03-31 | $348.02K 10-Q · filed 2024-05-15 | $626.17K derived: sum of 2 quarters · filed 2024-11-19 | $861.49K derived: sum of 3 quarters · filed 2024-11-19 | $1.01M derived: sum of 4 quarters · filed 2024-11-19 |
| 2022-12-31 | $278.14K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-19 | $513.46K derived: sum of 2 quarters · filed 2024-11-19 | $659.60K derived: sum of 3 quarters · filed 2024-11-19 | $822.20K 10-K/A · filed 2024-11-19 |
| 2022-09-30 | $235.32K 10-Q · filed 2023-11-13 | $381.46K derived: sum of 2 quarters · filed 2023-11-13 | $544.05K 10-Q · filed 2023-11-13 | $3.59M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $146.13K 10-Q · filed 2023-08-14 | $308.73K 10-Q · filed 2023-08-14 | $3.36M derived: sum of 3 quarters · filed 2023-08-14 | $3.58M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $162.60K 10-Q · filed 2023-05-15 | $3.21M derived: sum of 2 quarters · filed 2023-05-15 | $3.43M derived: sum of 3 quarters · filed 2023-05-15 | $3.64M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $3.27M derived: sum of 2 quarters · filed 2023-04-17 | $3.48M derived: sum of 3 quarters · filed 2023-04-17 | $4.16M 10-K · filed 2023-04-17 |
| 2021-09-30 | $218.87K 10-Q · filed 2022-11-14 | $427.35K derived: sum of 2 quarters · filed 2022-11-14 | $1.11M 10-Q · filed 2022-11-14 | $1.31M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $208.47K 10-Q · filed 2022-08-15 | $893.00K 10-Q · filed 2022-08-15 | $1.09M derived: sum of 3 quarters · filed 2022-08-15 | $1.43M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $684.52K 10-Q · filed 2022-05-16 | $881.10K derived: sum of 2 quarters · filed 2022-05-16 | $1.22M derived: sum of 3 quarters · filed 2022-05-16 | $1.46M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $196.57K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $532.64K derived: sum of 2 quarters · filed 2022-03-31 | $778.72K derived: sum of 3 quarters · filed 2022-03-31 | $1.04M 10-K · filed 2022-03-31 |
| 2020-09-30 | $336.07K 10-Q · filed 2021-11-15 | $582.14K derived: sum of 2 quarters · filed 2021-11-15 | $840.71K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $246.07K 10-Q · filed 2021-08-16 | $504.64K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $258.57K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |